StockData
Protara Therapeutics, Inc. logo

Protara Therapeutics, Inc. (TARA) stock

TARANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 7/30
$2.32−0.06 (-2.52%)

Close on Nov 17, 2026Market cap $137.10MP/E –Yield –

Protara Therapeutics ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Protara Therapeutics's ebitda for the twelve months ending Sep 30, 2017 was -$31.49M. For fiscal 2016 it was -$28.58M. The highest annual figure on record is -$7.10M in fiscal 2013.

Annual ebitda

PeriodPeriod endValueChange
FY2016Dec 31, 2016-$28.58M–
FY2015Dec 31, 2015-$20.81M–
FY2014Dec 31, 2014-$7.55M–
FY2013Dec 31, 2013-$7.10M–
FY2012Dec 31, 2012-$7.94M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2017Sep 30, 2017-$12.27M–
Q2 FY2017Jun 30, 2017-$5.95M–
Q1 FY2017Mar 31, 2017-$6.44M–
Q4 FY2016Dec 31, 2016-$6.83M–
Q3 FY2016Sep 30, 2016-$7.13M–

More Protara Therapeutics figures

See a number that looks wrong?